검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Durvalumab + Tremelimumab |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Malignant Solid Neoplasms |
Overview Indication | Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen |
MoA Biomarker | PD-L1-high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.. To evaluate the efficacy and safety of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) combined with durvalumab ± tremelimumab in patients with muscle-… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 37.4% |
Clinical ORR | 37.4% |
Clinical Result source | ClinicalTrials.gov NCT02542293 |
Clinical Data Tier / Score | A · 44 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Durvalumab + Tremelimumab |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Malignant Solid Neoplasms |
Overview Indication | Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen |
MoA Biomarker | PD-L1-high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.. To evaluate the efficacy and safety of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) combined with durvalumab ± tremelimumab in patients with muscle-… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 37.4% |
Clinical ORR | 37.4% |
Clinical Result source | ClinicalTrials.gov NCT02542293 |
Clinical Data Tier / Score | A · 44 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
추천 비교
추천 비교